1. Introduction
===============

Pharmacopuncture refers to be in the limelight acupuncture therapy that treat diseases by using techniques such as warming (Chunghwa), alcohol extraction or pressing to extract drugs from one or more oriental medicines and then injecting them into specific acupoints related to the disease and adjusting meridian functions \[[@B001]\]. *Carthamus tinctorious L*. is an annual safflower belonging to the family *Compositae*. *Cathami Semen* is the seed of the safflower and is composed of 20%-30% fatty oil (acids), whose main constituents are glycerides, linoleic acid, and oleic acid, as well as serotonin, serotonin conjugate, and serotobenin. *Carthamus tinctorious L*. contains Safflower-yellow cathamin, which reportedly extends blood vessels, excites the uterus, and reduces blood cholesterol. In oriental medicine, *Carthamus tinctorious L*. has warmness, which can affect detoxification, pain relief and blood circulation \[[@B002]\]. Carthmi-Flos herbal acupuncture (CF), a representative meridian pharmacopuncture medicine, is an oriental medicine made by extracting and refining oil from *Cathami Semen*.

CF was prepared in a sterile laborotary at the Korean Pharmacopuncture Institute (KPI). After the seeds had been cleaned, ground and peeled, they were screw pressed on a prepared mat. Rough unwanted residue was removed, and natural precipitation was induced. The extract from a 3-step filter was packaged with nitrogen \[[@B003]\]. Water soluble Carthmi-Flos herbal acupuncture (WCF) was prepared by homogenizing CF, water for injection (WFI) and an emulsifier.

Pharmacopuncture with *Carthamus tinctorious L*. is a representative pharmacopuncture method whose efficacy was demonstrated by many studies. Various studies on the effects of pharmacopuncture with *Carthamus tinctorious L*. in treating painful diseases, such as anti-pain effects in an arthritis model on experimental animals \[[@B004]\], pain-relief effects in degenerative knee arthritis patients \[[@B005]\], and effects in reducing backache according to the Oswestry Disability Index \[[@B006]\], were conducted, as were studies on immune-function and blood-vessel effects, including its anti-carcinogenic activity \[[@B007]\] and its effect on suppressing blood clots induced by endotoxin \[[@B008]\]. Other studies addressed hematological diseases (the treatment of alopecia areata by using pharmacopuncture with *Carthamus tinctorious L*.) \[[@B009]\], and gynecological diseases (the treatment of oligomenorrhea with pharmacopuncture and *Carthamus tinctorious L*.) \[[@B010]\]. Thus, the effects of pharmacopuncture combined with *Carthamus tinctorious L*. have been demonstrated in a variety of different fields.

Lim *et al*. studied the safety of pharmacopuncture with *Carthamus tinctorious L*. against skin irritation and eye irritation \[[@B011]\], and An *et al*. verified its safety through acute and subacute toxicity experiments \[[@B012]\]. Because pharmacopuncture with *Carthamus tinctorious L*. is expected to show gradual diversification of clinical use as an Oriental medicine, studies on toxicity, dose, and side effects must be pursued because pharmacopuncture inserts foreign substances into the human body. In this study, single intramuscular- dose toxicity tests were performed on rats to verify the safety and to identify any side effects of WCF prepared using *Carthamus tinctorious L*. Preliminary study was performed at Biotoxtech by non-Good Laboratory Practices (GLP). The 6 rats applied WCF 0.1mL dose. No rats died or showed abnormal finding. From this pilot study, main study's WCF dose determined to 1.0mL. These tests were performed by Biotoxtech according to GLP and the Standards of the Ministry of Food and Drug Safety as requested by the KPI. There was no conflict of interest.

2. Materials and Methods
========================

The WCF was provided by the KPI. WCF was developed to increase the treatment effects by increasing absorptivity and to reduce the side effects by reducing residue of existing CF. WCF was prepared in three steps: In step 1, CF, WFI and primary emulsifier were mixed together and homogenized for 30 minutes by using a high-speed homogenizer. Emulsifier was added in step 2 and homogenized at 30-80℃. In step 3, the temperature was reduced, and the mixture was homogenized to yield WCF. (Fig. [1](#F001){ref-type="fig"}).

![Flow diagram showing the manufacturing process of WCF pharmacopuncture.](2093-6966-v17-n01-027-g001){#F001}

Sprague-Dawley rats, purchased from Orientbio Inc., Korea, were used as experimental animals. The rats, 24 males and 24 females, were 5-weeks old with body weights of 111.8-135.8 g and 107.4-127.9 g, respectively. The animals were given a 7-day grace period to acclimatize before any measurements. General symptoms and body weights were observed to verify that no problems existed with the animals. During the grace period, individual subjects were marked, and at the end of the grace period, 20 males and 20 females closest to the standard body weight were selected and randomly divided into 4 groups of 5 male rats and 5 female rats so that the mean weights of the four groups were uniform.

Solid feed (Teklad Certified Irradiated Global 18% Protein Rodent Diet 2918C) and filtered tap water (Cheongju tap water filtered using a filter water sterilizer and irradiated with ultraviolet rays) were freely available. The breeding environment was as follows: a temperature of 20.0℃- 22.8℃, relative humidity of 48.5%-65.8%, 10- to 15-hour ventilation, 12-hour/day lighting cycle, and illuminesence of 150-300 Lux.

Intramuscular dose was selected because WCF is expected to be clinically applied to muscles. The clinical dose of WCF was 1.0 mL per application, as no fatalities had been observed at doses up to this value in preliminary tests (Biotoxtech Study No.: B12873P) on male and female rats. Thus, under consultation with the test's requester, 1.0-mL/ animal was configured as the high dose. Medium and low doses were 0.5- and 0.1-mL/animal; the same amount of saline solution, 1.0-mL/animal, was injected into the control group. (Table [1](#T001){ref-type="table"})

###### Groupings of the rats

  --------------------------------------------------------------------------------------------------------------------
  Group                 WCF injection\[mL\]   Saline-solution injection\[mL\]   Number of animals\   
                                                                                \[serial number\]\   
  --------------------- --------------------- --------------------------------- -------------------- -----------------
  G1: control group     0                     1.0                               5 \[1101-1105\]      5 \[2101-2105\]

  G2: low-dose group    0.1                   0                                 5 \[1201-1205\]      5 \[2201-2205\]

  G3: mid-dose group    0.5                   0                                 5 \[1301-1305\]      5 \[2301-2305\]

  G4: high-dose group   1.0                   0                                 5 \[1401-1405\]      5 \[2401-2405\]
  --------------------------------------------------------------------------------------------------------------------

Injection was performed using a disposable syringe (1 mL, 26 G). Single doses were injected into the left femoral muscle for the low-dose and the medium-dose groups. For the control and the high-dose groups, single injections, 0.5 mL/site, were done into the left and the right femoral muscles. On the day of injection (day 0), clinical symptoms and fatalities were observed at 30 minutes and at 1, 2, 4 and 6 hours after injection. From day 1 to day 14, general symptoms were observed once a day. Body weights were measured (CP3202S scale) on days of injection (before injection) and on days 3, 7 and 14. For the hematology test, blood was collected from the abdominal aorta on day 15 after applying anesthesia by isoflurane. Hematological analyses were carried out by placing 1 mL of collected blood into a tube containing ethylenediaminetetraacetic acid, which was then analyzed using a blood corpuscle analyzer (ADVIA 120, SIEMENS, Germany). For the coagulation test, about 2 mL of collected blood was placed in a tube containing 3.2% sodium citrate and centrifuged for 10 minutes at 3,000 rpm, after which the blood plasma was collected. Measurement was done using a coagulation time analyzer (Coapresta 2000, SEKISUI, Japan). The prothrombin time and the activated partial thromboplastin time (APTT) were measured. After completing the hematology tests, for the clinical chemistry test, we centrifuged the remaining blood for 10 minutes at 3,000 rpm and collected the blood serum. A clinical chemistry analyzer (7180, Hitachi, Japan) and an electrolyte analyzer (AVL9181, Roche, Germany) were used.

Visual inspection of all body organs and tissues was performed on all animals after necropsy. Body organs and tissues were extracted and fixed in 10% neutral buffered formalin, and histopathological observations were carried out.

Body-weight, hematology and clinical chemistry results were tested using SAS (version 9.3, SAS Institute Inc., USA). Bartlett tests were performed for homo-scedasticity (significance level: 0.05). For homo-scedasticity, one-way analysis of variance tests were performed to yield the significance (significance level: 0.05), and multiple Dunnett's *t*-tests were carried out (significance level: 0.05 on both sides and 0.01). For hetero-scedasticity, significance (significance level: 0.05) was checked using the Kruskal-Wallis test.

3. Results
==========

In this study, no mortalities were caused by injecting intramuscular doses of WCF. Accordingly, computation of the LD~50~ was impossible; however, a single intramuscular dose of WCF at 1.0 mL/animal caused no mortalities. (Table [2](#T002){ref-type="table"})

No abnormal clinical symptoms (type of toxicity symptom, time of expression, time of recovery, etc.) were observed on the day of injection (day 0) at 30 minutes and at 1, 2, 4 and 6 hours after injection, as was the case for days 1 to 14 after injection. All groups showed a continued increase in body weight, but the differences among the groups were not significant. (Fig. [2](#F002){ref-type="fig"}. Tables [3](#T003){ref-type="table"}, [4](#T004){ref-type="table"}, [5](#T005){ref-type="table"})

Hematological analyses on the rats'blood showed WCF to have no effect. However, APTT (sec) mean of the G3 female group showed a statistically significant change (*P* \< 0.01),but it was a miscellaneous change with no dose dependence, clinical meaning or toxicological meaning. Clinical chemistry analyses showed no significant differences for any of the measured items between the normal saline and the WCF groups. In no male or female experimental group were visual abnormalities observed. (Tables [6](#T006){ref-type="table"}, [7](#T007){ref-type="table"}, [8](#T008){ref-type="table"})

On the histopathological tests, one female in the highdose group showed infiltration of mononuclear cells and a multi-nucleated giant cell around eosinophilic materials caused by WCF in an area similar to a cross section of muscular fiber, and 8 eosinophilic materials were clustered at a local part. No abnormalities were observed in any other subjects. (Table [9](#T009){ref-type="table"})

###### Mortality

  -------------------------------------------------------------------------------------------
  Group   WCF injection\[mL\]   Saline-solution injection\[mL\]   Mortality \[%\]\       
                                                                  \[% = dead/tested\]\   
  ------- --------------------- --------------------------------- ---------------------- ----
  G1      0                     1.0                               0%                     0%

  0       1.0                   \[0/5\]                           \[0/5\]                

  G2      0.1                   0                                 0%                     0%

  0.1     0                     \[0/5\]                           \[0/5\]                

  G3      0.5                   0                                 0%                     0%

  0.5     0                     \[0/5\]                           \[0/5\]                

  G4      1.0                   0                                 0%                     0%

  1.0     0                     \[0/5\]                           \[0/5\]                
  -------------------------------------------------------------------------------------------

###### Clinical signs on day 0

  Group   WCF injection\[mL\]   Saline-solution injection\[mL\]   Sex    Hours after dosing   Clinical signs                 
  ------- --------------------- --------------------------------- ------ -------------------- ---------------- --- --- ----- -------
  G1      0                     1.0                               Male   5                    5                5   5   5     NOA\*
  0       1.0                   Female                            5      5                    5                5   5   NOA   
  G2      0.1                   0                                 Male   5                    5                5   5   5     NOA
  0.1     0                     Female                            5      5                    5                5   5   NOA   
  G3      0.5                   0                                 Male   5                    5                5   5   5     NOA
  0.5     0                     Female                            5      5                    5                5   5   NOA   
  G4      1.0                   0                                 Male   5                    5                5   5   5     NOA
  1.0     0                     Female                            5      5                    5                5   5   NOA   

\*NOA: No observable abnormality

4. Discussion
=============

WCF is prepared by homogenizing a mixture of CF, WFI and emulsifier and increases the treatment efficacy while maintaining the characteristics of existing CF. The effects of CF have been demonstrated by various studies; i.e., CF can be used for pain relief, is effective for a variety of different pains \[[@B013]\], increases regional cerebral blood flow significantly \[[@B014]\], and can be used in a variety of different fields with different effects such as anti-carcinogenic \[[@B007], [@B012]\] and anti-oxidative \[[@B015]\] effects.

In this experiment, an intramuscular-dose toxicity test of WCF was performed by Biotoxtech to evaluate the safety of WCF manufactured by the KPI according to the GLP. No mortalities occurred in any group. Also, observations taken after injection of WCF showed no abnormalities in the clinical symptoms of the four groups. No significant bodyweight differences were observed in any of the groups. Hematologically, a change in the APTT (sec) mean value of the G3 female group was observed, but had no clinical or toxicological meaning. Clinical chemistry tests showed no differences between the control and experimental groups. No visual abnormalities were observed in any group at necropsy. Finally, histopathological observation showed that WCF caused a change in one female in the high-dose group. Visual examination showed the subject to have suffered infiltration of mononuclear cell and to have had a multi-nucleated giant cell around eosinophilic material. No abnormalities were observed in any other subjects.

Studies on the side effects and the safety of CF are continuously being conducted. According to \[[@B003]\], pain, flare and edema were found in the surgical parts in patients after CF therapy. After 4 days, side effects, such as flare and edema, mostly disappeared. They were thought to have occurred due to a mixture of highly-toxic drugs in the oil press during CF during preparation \[[@B003]\]. Side effects created by CF were reported in \[[@B016]\]. Suppuration and pain appeared in the surgical parts in 1 patient who received CF therapy of 0.1 mL/1 time/week for 8 months and 1 patient who received CF therapy of 0.1 mL/1-3 times/week for 3 months.
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###### Clinical signs from day 1 to day 14

  Group   WCF injection\[mL\]   Saline-solution injection\[mL\]   Sex    Hours after dosing   Clinical signs                                                     
  ------- --------------------- --------------------------------- ------ -------------------- ---------------- --- --- --- --- --- --- --- --- --- --- --- ----- -----
  G1      0                     1.0                               Male   5                    5                5   5   5   5   5   5   5   5   5   5   5   5     NOA
  0       1.0                   Female                            5      5                    5                5   5   5   5   5   5   5   5   5   5   5   NOA   
  G2      0.1                   0                                 Male   5                    5                5   5   5   5   5   5   5   5   5   5   5   5     NOA
  0.1     0                     Female                            5      5                    5                5   5   5   5   5   5   5   5   5   5   5   NOA   
  G3      0.5                   0                                 Male   5                    5                5   5   5   5   5   5   5   5   5   5   5   5     NOA
  0.5     0                     Female                            5      5                    5                5   5   5   5   5   5   5   5   5   5   5   NOA   
  G4      1.0                   0                                 Male   5                    5                5   5   5   5   5   5   5   5   5   5   5   5     NOA
  1.0     0                     Female                            5      5                    5                5   5   5   5   5   5   5   5   5   5   5   NOA   

###### Body weights

  Group   WCF injection\[mL\]   Saline-solution injection \[mL\]   Sex    Weight in grams at 0, 3, 7, 14 days   Gain 0-14                           
  ------- --------------------- ---------------------------------- ------ ------------------------------------- ----------- ------- ------- ------- -------
  G1      0                     1.0                                Male   Mean                                  195.4       221.7   260.6   316.5   121.1
  0       1.0                   Male                               S.D.   5.0                                   8.5         10.5    16.4    14.1    
  0       1.0                   Male                               N      5                                     5           5       5       5       
  0       1.0                   Female                             Mean   163.6                                 176.6       193.9   218.8   55.2    
  0       1.0                   Female                             S.D.   6.9                                   10.0        8.8     14.3    8.9     
  0       1.0                   Female                             N      5                                     5           5       5       5       
  G2      0.1                   0                                  Male   Mean                                  192.4       219.6   257.1   306.1   113.7
  0.1     0                     Male                               S.D.   5.1                                   6.1         9.8     13.5    9.8     
  0.1     0                     Male                               N      5                                     5           5       5       5       
  0.1     0                     Female                             Mean   163.6                                 175.2       189.9   214.8   51.1    
  0.1     0                     Female                             S.D.   6.5                                   5.6         8.6     9.5     6.8     
  0.1     0                     Female                             N      5                                     5           5       5       5       
  G3      0.5                   0                                  Male   Mean                                  194.1       220.8   256.8   308.5   114.4
  0.5     0                     Male                               S.D.   8.4                                   8.8         11.3    21.0    14.7    
  0.5     0                     Male                               N      5                                     5           5       5       5       
  0.5     0                     Female                             Mean   163.5                                 176.7       190.3   217.8   54.4    
  0.5     0                     Female                             S.D.   8.8                                   9.9         12.3    13.6    7.2     
  0.5     0                     Female                             N      5                                     5           5       5       5       
  G4      1.0                   0                                  Male   Mean                                  192.4       216.3   249.7   295.7   103.3
  1.0     0                     Male                               S.D.   7.6                                   8.2         10.7    18.0    15.9    
  1.0     0                     Male                               N      5                                     5           5       5       5       
  1.0     0                     Female                             Mean   162.5                                 178.3       191.6   217.9   55.3    
  1.0     0                     Female                             S.D.   8.4                                   7.4         7.4     8.8     3.9     
  1.0     0                     Female                             N      5                                     5           5       5       5       

###### Hematology findings

  ------------------------------------------------------------------------------------------------------------------------------------------
  Group   WCF injection\   Saline-solution\                             Male   Female   Abnormality value
          WCF \[mL\]\      injection \[mL\]\                                            
  ------- ---------------- ------------------- ------------------------ ------ -------- ----------------------------------------------------
  G1      0                1.0                 No abnormalities found   V      V        No abnormalities

  G2      0.1              0                   No abnormalities found   V      V        No abnormalities

  G3      0.5              0                   No abnormalities found   V               Female - APTT:Mean 14.4 (P\<0.01:Dunnett's t-test)

  G4      1.0              0                   No abnormalities found   V      V        No abnormalities
  ------------------------------------------------------------------------------------------------------------------------------------------

###### Clinical chemistry findings

  -------------------------------------------------------------------------------------
  Group   WCF injection\   Saline-solution\                             Male   Female
          WCF \[mL\]\      injection \[mL\]\                                   
  ------- ---------------- ------------------- ------------------------ ------ --------
  G1      0                1.0                 No abnormalities found   V      V

  G2      0.1              0                   No abnormalities found   V      V

  G3      0.5              0                   No abnormalities found   V      V

  G4      1.0              0                   No abnormalities found   V      V
  -------------------------------------------------------------------------------------

###### Necropsy findings

  Sex                      Male   Female                                
  ------------------------ ------ -------- ----- ----- ---- ----- ----- -----
  Group                    G1     G2       G3    G4    G1   G2    G3    G4
  Dose (mL/animal)         0      0.1      0.5   1.0   0    0.1   0.5   1.0
  Number of animals        5      5        5     5     5    5     5     5
  No abnormalities found   5      5        5     5     5    5     5     5

###### Histopathological change findings

  Organ            Sex                      Male   Female                                
  ---------------- ------------------------ ------ -------- ----- ----- ---- ----- ----- -----
  Injection site   Group                    G1     G2       G3    G4    G1   G2    G3    G4
  Injection site   Dose (mL/animal)         0      0.1      0.5   1.0   0    0.1   0.5   1.0
  Injection site   Number of animals        5      5        5     5     5    5     5     5
  Injection site   No abnormalities found   5      5        5     5     5    5     5     4
  Injection site   Remarkable findings      0      0        0     0     0    0     0     1\*

\* Infiltration, mononuclear cells and multinucleated giant cells around eosinophilic materials. Grade - minimal

Unlike in \[[@B003]\], the side effects were deemed to be due to an accumulation of CF in the human body from long-term therapy \[[@B016]\]. The safety of CF was reported in \[[@B012]\] based on a toxicity test of CF, but this was only a short-term study on acute and subacute toxicity. Chronic toxicity tests on CF must be carried out in the future.

Although histological abnormalities caused by WCF were found in a subject of the high-dose group in this experiment, according to \[[@B017]\], no histological abnormalities were observed in Sprague-Dawley rats treated with CF 3 times a week for 1-2 weeks. However, the group with 4 weeks of therapy showed histological ambiguity regarding the boundary of muscular tissues, observation of flares, and induction of inflammations \[[@B017]\]. A histological study with a greater number of subjects and a longer period is deemed necessary to examine long-term or high-dose effects of CF or WCF.

The safety of CF was demonstrated, but its side effects were presented in several studies. However, studies on the safety and the side effects of WCF are lacking. Thus, the toxicity and the safety of WCF must be investigated, and long-term histological studies based on large numbers of subjects are deemed necessary.

5. Conclusion
=============

The results of single intramuscular-dose toxicity tests with WCF on 4 groups of Sprague-Dawley rats, 3 experimental groups (0.1 mL/animal, 0.5 mL/animal and 1.0 mL/animal) and 1 control group (1.0 mL/animal of saline solution), are as follows:

1.  In all groups no mortalities occurred.

2.  There was no abnormalities in clinical symptoms, body-weight, hematology tests, clinical chemistry tests, necropsy, histopathological tests.

3.  In 1.0 mL/animal dose of WCF, we could not found toxicity of WCF for both males and females Rats.

This study do not show WCF's safety of human body. To examine the safety of WCF, we need to carry out testing to check whether or not the toxicity would have negative effects on human body.

This work was supported by Woosuk University research funds in 2013.

[^1]: **\*** Both authors contributed equally to this work.
